Making the Case for Negative Control Outcome Studies in a Real-World Evidence Setting

NCO studies are methodologically valuable for detecting unmeasured confounding, but the practical case for including them as a required component of a real-world evidence generation workflow had not been formally articulated for regulatory audiences.

Target RWE researchers presented an oral lecture synthesizing the scientific rationale, practical implementation steps, and regulatory value proposition for NCO studies as a standard gating mechanism in RWE programs.

Articulating the NCO business and scientific case establishes NCO gating as a recognized Target RWE differentiator, supporting the company's positioning with pharma partners and regulators who require evidence of analytic rigor.

NCO study case-making for regulatory-grade RWE gating mechanism in pharma partner programs, Thought leadership positioning of NCO-based validity checking as an RWE industry standard